Articles tagged with Drug Studies
A study by Johns Hopkins Medicine researchers found that psilocybin-assisted therapy can lead to significant and durable improvements in depression, with effects lasting at least a year for most patients. The treatment was shown to produce large decreases in depression severity and stable rates of response throughout the follow-up period.
Researchers at NTU Singapore have developed a new method to generate sulphur pharmacophores, which are crucial for drug discovery. The method uses a catalyst called pentanidium and can produce multiple variations of pharmacophores, making the process more efficient and fruitful.
A new study from China suggests that tenecteplase, a bioengineered variant of alteplase, may increase the time for stroke treatment beyond 4.5 hours, potentially saving lives. The medication appears safe and potent in reestablishing blood flow through blocked brain vessels, but more research is needed to understand its effectiveness in...
The anticholinergic burden scale helps identify patients at risk of cognitive decline from these medications. The editorial highlights the complexity of safely reducing or stopping these medications due to their risks.
A clinical trial of niclosamide in COVID-19 patients found signals of benefit warranting further study. The medication showed potential in reducing contagiousness and symptoms, particularly in higher-risk populations.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare cancer affecting up to 1 in 1 million women worldwide, characterized by uncontrolled tumor cell growth. Researchers aim to identify new therapeutic targets using extracellular vesicles, with the goal of developing new therapies for LAM patients.
A recent study found that using personal assistant applications on smartphones can significantly improve memory in older adults with dementia. The researchers trained participants to use the technology to receive reminders about daily events and activities, resulting in improved memory performance.
A large study analyzed administrative health data from Ontario and found a low risk of major anomalies with tramadol and morphine, minor anomalies with codeine, hydromorphone, and oxycodone exposure. The study highlights the need to consider both the benefits and harms of opioid treatment during pregnancy.
A recent study published in The Lancet Respiratory Medicine found that baricitinib significantly reduced all-cause mortality in critically ill COVID patients on mechanical ventilation. The drug showed a 62% lower mortality rate compared to placebo, with one additional life saved for every six people treated with baricitinib.
A study estimates that switching from capsule to tablet or ointment and cream forms of prescription drugs can result in significant cost savings for insured patients. The analysis found potential savings ranging from $500 to $1,400 per year.
Researchers analyzed data from hospitals in the US, Australia, and New Zealand to compare alteplase and tenecteplase for treating ischemic strokes. The study found that patients treated with tenecteplase had significantly lower rates of serious bleeding into the brain compared to those treated with alteplase.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
A new generation of cholesterol-lowering drugs is being developed to target the PCSK9 protein, which regulates LDL receptor degradation on cells. These therapies have shown promise in reducing LDL levels with fewer side effects than statins.
A recent study found an increase in intentional drug overdose deaths among young people aged 15-24, older adults aged 75-84, and non-Hispanic Black women. Despite a downward trend in overall deaths, these subgroups saw a rise in intentional overdose death rates, with women ages 45 to 64 having the highest rates.
Researchers have identified the impact of protein corona formation on nanoparticles' physiochemical and biological properties. This knowledge can be used to optimize carriers for nanomedical applications, improving the efficiency and effectiveness of biopharmaceutical delivery.
A Phase 1 clinical trial conducted by University of Minnesota researchers demonstrates the safety and efficacy of a novel immunotherapy drug in treating human immunodeficiency virus (HIV). Participants showed a significant decrease in HIV-infected cells in their blood for up to six months following treatment.
Researchers at Johns Hopkins Medicine have successfully transplanted a kidney from a COVID-19 donor, demonstrating that healthy kidneys from such donors can be safely transplanted. The recipient has shown no signs or symptoms of the virus and has excellent kidney function since the transplant.
A new study aims to improve antibody responses in kidney and liver transplant recipients to COVID-19 mRNA vaccine doses, exploring the impact of reduced immunosuppressive medication. The CPAT-ISR trial will enroll up to 400 adults with a history of organ transplants and evaluate the effectiveness of this strategy.
Researchers at Oregon State University have identified two hemp compounds that can block the coronavirus from entering human cells. Preclinical trials are expected to begin within a few months, and the study's findings suggest these compounds may be effective against variants of SARS-CoV-2.
A comprehensive study investigates the metabolism of four drugs in rabbit eyes, revealing different enzyme profiles from liver metabolism. The findings provide valuable information for advancing ophthalmic drug development.
A clinical trial found that combining remdesivir with hyperimmune intravenous immunoglobulin did not improve health status or safety for adults hospitalized with COVID-19. The trial also showed a higher risk of adverse outcomes among patients who generated SARS-CoV-2-neutralizing antibodies before treatment.
Lab tests show current anti-COVID pills remain effective against omicron, but available antibody therapies are substantially less effective. Researchers tested various treatments and found that some antibodies have lost their ability to neutralize omicron at realistic dosages.
Researchers found minority groups were less likely to start newer diabetes medications, despite needing them most. The study used data from nearly 5,000 patients with type 2 diabetes and showed Black patients were 20% less likely and American Indian or Alaskan Native patients were 50% less likely to initiate treatment.
A randomized controlled trial of combinatorial pharmacogenetics testing found no significant improvement in depressive symptoms among adolescents with depression. However, the study suggests that testing results may influence physician decision-making and could be useful in specific cases where individual gene-drug pairs impact clinica...
A new study reveals that the Omicron variant is sensitive to inhibition by the interferon response, an unspecific immune reaction present in all body cells. This provides the first explanation for why COVID-19 patients infected with Omicron are less likely to experience severe disease.
Researchers developed an experimental drug that silences a faulty FUS gene, potentially treating rare and aggressive forms of ALS. The treatment delayed motor neuron degeneration in mice and showed promise in a patient with FUS-ALS.
A new study found that disease-modifying antirheumatic drugs do not protect people with rheumatoid arthritis from developing Parkinson's disease. However, using chloroquine or hydroxychloroquine was associated with a lower risk of PD. The study controlled for various factors, including comorbidities and age.
A retrospective analysis of 13 clinical trials found that most combination therapies involving immune checkpoint inhibitors worked due to independent drug action, rather than synergy or additivity. This discovery has implications for cancer clinical trial design and may help improve treatment outcomes.
A new review and meta-analysis found that drug companies are increasingly disclosing negative study findings for antidepressants. While progress has been made, full transparency remains an issue, with researchers emphasizing the need to report all trial results, both positive and negative, to inform patient treatment.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
A randomized controlled trial found that remdesivir reduced the need for mechanical ventilation in hospitalized patients with COVID-19. The study involved 1282 patients and showed that those treated with remdesivir were able to come off oxygen and ventilators sooner than those receiving standard care.
Rice University researchers developed a microfluidic platform to analyze how infectious bacteria evolve resistance to antibiotics. The platform allows for controlled environments and fine-tuning of conditions, revealing previously unknown pathways to resistance.
Researchers found that a third of patients with wet age-related macular degeneration can safely stop eye injection therapy without further vision loss. Patients who stopped treatment showed better visual acuity, gain of vision, and less fluid in their retina compared to those requiring continued injections.
Research from the University of Virginia Health System found that long-term use of ACE inhibitors and angiotensin receptor blockers can lead to hardened kidney vessels. The drugs, commonly prescribed for high blood pressure and heart failure, were associated with damage in both lab mice and humans.
A clinical trial found that people with severe alcohol disorder stayed off alcohol for longer when treated with low doses of ketamine combined with psychological therapy. The therapy showed promise in preventing relapse and improving liver function, with participants having lower depression rates after three months.
Researchers found that increasing the solution pH makes niclosamide effective against SARS-COV-2 virus replication. A lower dose of niclosamide can also positively affect airway cells without harming them. This could enable safe and effective nose and throat sprays with added protection.
A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
A randomized controlled trial involving 51 GP practices and 404 patients found a significant reduction in the number of medicines prescribed for older people with multimorbidity. The intervention group experienced over 800 medicines being stopped, with only mild adverse reactions reported.
Researchers found that chronic use of sildenafil aggravated the development of abdominal aortic aneurysms in mice, disrupting smooth muscle cells' ability to contract. The study suggests caution when prescribing PDE5 inhibitors like sildenafil for patients with existing aortic aneurysmal lesions.
Aspirin use in primary prevention of cardiovascular disease should be individualized based on benefit-to-risk assessment, not age. The authors' updated meta-analysis shows a 13% reduction in cardiovascular disease with similar benefits at older ages.
Researchers found that psilocybin doses of 10mg or 25mg administered simultaneously to up to six participants had no adverse effects. The study also showed promise for treating treatment-resistant depression and PTSD.
A study found that 88% of ED patients with suspected septic olecranon bursitis who received empiric antibiotics without aspiration resolved without needing further treatment. Conservative management may be a reasonable approach for select patients, potentially streamlining care and reducing complications.
Researchers found that Botox-treated patients reported anxiety significantly less often than those undergoing different treatments for similar conditions. The data used was from the FDA's Adverse Effect Reporting System and showed a 22-72% lower risk of anxiety for four out of eight conditions and injection sites.
A new clinical trial is enrolling young people with rare genetic mutations that cause early-onset Alzheimer's disease. The study will test gantenerumab to prevent the buildup of toxic protein amyloid beta, which can slow or stop the disease.
Researchers found that certain bacteria in the human microbiome can produce an enzyme called acarbose kinase, which renders acarbose inactive. This enzyme is present in three major categories of oral and gut bacteria and may make people resistant to the antidiabetic drug.
Families of children with serious illnesses have higher rates of healthcare use and physical/mental health issues compared to those without such conditions. The study included 6,900 children and found significant associations between family health outcomes and the child's condition.
A review suggests that doctors should prescribe fewer antidepressants and for shorter periods due to the potential severity and duration of withdrawal symptoms. The use of antidepressants is also associated with a range of side effects, but clinical trial data often don't assess outcomes that matter most to patients.
Researchers at Tel Aviv University successfully treated autism in animal models with medical cannabis oil, improving behavioral and biochemical parameters. The treatment showed significant improvement in compulsive and anxious behaviors, and a decrease in the concentration of the arousing neurotransmitter glutamate.
A study of 1.1 million patients with type 2 diabetes found disparities in the use of GLP-1 receptor agonists by racial and ethnic groups, as well as by sex and socioeconomic status. The findings highlight concerns about unequal access to effective diabetes care.
A proof-of-concept trial has identified a drug that may offer benefit to some patients hospitalised with COVID-19 pneumonia. The study found namilumab reduced inflammation and improved outcomes in patients with high CRP levels, but further research is needed for definitive results.
A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.
New research suggests that cannabis use can lead to harmful drug-drug interactions by interfering with two families of enzymes that metabolize a wide range of drugs. This could result in unintended side effects such as toxicity or accidental overdose, particularly for older individuals using medications.
A new evidence review by Oregon Health & Science University researchers found that the expensive multiple sclerosis drug Acthar provides very little clinical benefit compared to less-expensive alternatives. The study screened 41 studies and found weak or no benefit from Acthar against standard medications like corticosteroids.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
Researchers from Aarhus University have shown that the approved medicine Atovaquone has a protective effect on human lung cells in laboratory settings, potentially preventing Covid-19 infection. The study reveals its potent antiviral properties against various coronavirus variants, offering hope for a new treatment option.
A new NRG Oncology clinical trial found that bupropion did not improve sexual desire in female cancer survivors. The trial evaluated the effects of extended-release bupropion on postmenopausal women with low baseline sexual desire scores.
A recent study found that patients with hormone receptor-positive breast cancer who experience rising ESR1 mutations before disease progression can benefit from an early switch to fulvestrant plus palbociclib. This approach yields a statistically and clinically significant gain in progression-free survival, potentially justifying its a...
A NIH study has identified a molecular link between a gene mutation and late-onset retinal degeneration, a rare eye disease. The researchers found that the diabetes drug metformin and gene therapy may be effective treatments for the condition, which can cause abnormal blood vessel growth and deposits of apolipoprotein E.
A recent study found that pathologic complete response rates did not differ by racial groups, but HR-positive/HER2-negative breast cancer showed a significant survival disparity between Black and white women. The study suggests that tumor molecular subtype is a more significant factor in breast cancer survival than race.